Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Artelo Biosciences ( (ARTL) ) just unveiled an announcement.
Artelo Biosciences convened but then adjourned its 2025 annual meeting of stockholders on December 31, 2025 without conducting any business due to a lack of quorum, and plans to reconvene the meeting on January 30, 2026 to allow more time for shareholders to vote on existing proposals and the ratification of its independent auditor for the 2026 fiscal year. After notifying Nasdaq that the annual meeting had been adjourned, the company received a notice on January 14, 2026 stating it was not in compliance with Nasdaq’s requirement to hold an annual meeting within one year of fiscal year-end, which may serve as an additional basis for delisting alongside its previously disclosed shortfall in minimum stockholders’ equity; while the notice does not immediately affect trading of its shares, the company has presented a plan to regain compliance to a Nasdaq hearing panel, though there is no assurance its efforts will succeed.
The most recent analyst rating on (ARTL) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Artelo Biosciences stock, see the ARTL Stock Forecast page.
Spark’s Take on ARTL Stock
According to Spark, TipRanks’ AI Analyst, ARTL is a Underperform.
The score is driven primarily by very weak financial performance (zero revenue, widening losses, sustained cash burn, and negative equity), which elevates financing and dilution/solvency risk. Technicals add further pressure with a clear downtrend and negative momentum, while valuation provides little offset because earnings are negative and no dividend yield support is available.
To see Spark’s full report on ARTL stock, click here.
More about Artelo Biosciences
Artelo Biosciences, Inc. is a Nasdaq-listed biopharmaceutical company focused on developing proprietary therapeutics, with its operations and investor base governed by U.S. securities and stock exchange listing rules.
Average Trading Volume: 638,480
Technical Sentiment Signal: Sell
Current Market Cap: $3.25M
For detailed information about ARTL stock, go to TipRanks’ Stock Analysis page.